{{Rsnum
|rsid=7012413
|Gene=FGFR1
|Chromosome=8
|position=38459880
|Orientation=plus
|GMAF=0.3861
|Gene_s=FGFR1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 49.1 | 44.6 | 6.2
| HCB | 44.4 | 42.2 | 13.3
| JPT | 50.4 | 43.4 | 6.2
| YRI | 13.1 | 37.9 | 49.0
| ASW | 19.3 | 43.9 | 36.8
| CHB | 44.4 | 42.2 | 13.3
| CHD | 40.4 | 48.6 | 11.0
| GIH | 43.6 | 50.5 | 5.9
| LWK | 10.0 | 52.7 | 37.3
| MEX | 52.6 | 42.1 | 5.3
| MKK | 24.4 | 55.8 | 19.9
| TSI | 52.5 | 43.6 | 4.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=23232491
|Title=A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528
}}

{{PMID Auto
|PMID=20717167
|Title=FGF21 signalling pathway and metabolic traits - genetic association analysis.
|OA=1
}}

{{PMID Auto
|PMID=21430024
|Title=Genetic association and gene expression analysis identify FGFR1 as a new susceptibility gene for human obesity.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}